Connect With Us

Inside INdiana Business
Subscribe Now Log In
  • Home
  • News
    • Education
    • Health
    • Tech
    • STEM
    • Advanced Manufacturing & Logistics
    • Life Sciences
    • Ag INnovation
    • INPower
  • Videos
  • Big Wigs
    • Submit Big Wigs
  • Events
    • Engage Central Indiana – Indianapolis
    • Engage Northeast Indiana – Fort Wayne
    • Engage West Central Indiana – Terre Haute
    • Engage Greater Lafayette – West Lafayette
    • Engage Northwest Indiana – Valparaiso
    • Engage South Bend – Elkhart
    • Engage Southwest Indiana – Evansville
  • Newsletters
  • Podcasts
  • On-Air
    • TV & Radio Listings
  • Contact
    • About IIB
    • Meet the Team
    • Contact Us
    • Advertise
    • Gift Cards
    • Flagship Stations
    • Gerry’s Message
    • Speaking Engagement Request

Connect With Us

Potential Treatments Making Strides For Lilly

Tuesday, June 7, 2016 02:01 PM EDT
Potential Treatments Making Strides For Lilly Lilly completed the CoLucid acquisition in March.

Indianapolis-based Eli Lilly and Co. (NYSE: LLY) says new studies on two potential lung cancer treatments are showing "encouraging" signs. The company presented data on early-phase trials on combinations of Alimta and Cyramza with Merck’s Keytruda at last week’s 52nd Annual Meeting of the American Society of Clinical Oncology.

The results involve patients with non-small cell lung cancer. Lilly Oncology Senior Vice President of Product Development And Medical Affairs Richard Gaynor says "these early data from the combinations of ALIMTA and KEYTRUDA in front-line nonsquamous NSCLC and CYRAMZA and KEYTRUDA in later lines of NSCLC are encouraging. We eagerly await Phase 2 and Phase 3 data with the ALIMTA and KEYTRUDA combinations and more mature data with the CYRAMZA and KEYTRUDA combination, in NSCLC, gastric and bladder cancers, to better understand the role of immuno-oncology combinations in improving patient outcomes in these settings." Gaynor also says the company is making progress on its research and development strategy, which involves three areas: tumor cell signaling, tumor microenvironment and immuno-oncology.

You can connect to more about the announcement by clicking here.

Story Continues Below

Most Popular Stories

  • Shareholders approve $485M Kimball acquisition

  • Finding your ‘why’ in community service

  • Terre Haute expecting thousands for baseball tourney

  • After bipartisan House vote, debt ceiling deal now goes to Senate

  • What to expect from likely appeals in abortion doc case

  • Indiana Conference for Women names new executive director

Perspectives

Finding your ‘why’ in community service

Finding your ‘why’ in community service

There is a notable energy in the Central Indiana community that drives many of us to want to support the non-profit organizations that make our city a better place for us all to live. Whether you are interested in social services, animal welfare, public safety, the arts, veterans’ services, education, entrepreneurship, sports, environment, senior issues, food stability and so many more - there is no shortage of need and opportunity to become involved....

Inside INdiana Business

Inside INdiana Business
A division of IBJ Media

1 Monument Circle, Suite 300
Indianapolis, IN 46204

PHONE: (317) 634-6200

FAX: (317) 263-5060

NEWSLETTER@IIBNEWS.COM

  • Home
  • News
  • Videos
  • Gerry Dick
  • Newsletters
  • On-Air
  • Contact

Copyright © 2023 All Rights Reserved Privacy Policy | Terms of Service